TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (NCT06001762), a na phase 2 study. The primary outcome is Composite Endpoint: Number of Participants With Abemaciclib Discontinuation for Any Reason, Abemaciclib Dose Reductions, or the Inability of Study Participants to Reach the Target Dose of Abemaciclib (Full Dose 150 mg BID) at 3 Months (12 Weeks).

2. Clinical Question

The study concerns tolerability during treatment, rather than a randomized test of cancer outcomes between two dosing strategies. Its stated rationale is to assess whether increasing the dose may have fewer side effects and be better tolerated than the standard dosage. That is the question motivating the study, not a conclusion established by the design or the posted data.

Endocrine therapy listed in the record includes tamoxifen, anastrozole, letrozole, exemestane, and an LHRH agonist. The record does not give enough detail to describe how endocrine therapy choices were assigned or to compare outcomes across those therapies.

3. Trial Design

TRADE is registered as a phase 2, single-group study sponsored by Dana-Farber Cancer Institute. The registry lists allocation as not applicable and masking as none. There is no randomized control arm, so the study can describe what happened among participants following the study strategy but cannot, by itself, estimate a controlled difference between dose escalation and standard dosing.

The registry lists enrollment of 90. The primary endpoint concerns participants who received at least one dose of abemaciclib and did not progress within 12 weeks of starting treatment. The record states that one participant with progression within 12 weeks was excluded from the primary endpoint analysis. It does not report the primary analysis denominator or the endpoint count.

The study describes abemaciclib as given twice daily at a predetermined dose during treatment cycles, with endocrine therapy once daily. The named target full dose is 150 mg BID. The available arm description is incomplete, so further details of the dose-escalation schedule, visit schedule, or treatment modifications are not reported in the registry record.

The registry lists a start date of 2023-10-05, a primary completion date of 2025-01-22, and a status of active, not recruiting. The listed primary completion date is a registry milestone; it does not establish that the primary analysis result has been posted.

The record lists 17 outcome measures and one analysis. It does not report the statistical analysis plan, any interim analyses, or a sample-size justification for the trial itself. Planning assumptions associated with sample-size illustrations should not be read as a description of the study’s actual design: the trial is single-group, whereas those assumptions describe equal allocation between two arms.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Subjects who received at least one dose of abemaciclib and did not progress within 12 weeks of starting treatment. One (1) subject had a progression event within 12 weeks of starting treatment. Therefore, this subject is excluded from the primary endpoint analysis.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: All 90 subjects enrolled in the TRADE trial

6. Primary Endpoint

The registry lists the primary outcome as Composite Endpoint: Number of Participants With Abemaciclib Discontinuation for Any Reason, Abemaciclib Dose Reductions, or the Inability of Study Participants to Reach the Target Dose of Abemaciclib (Full Dose 150 mg BID) at 3 Months (12 Weeks), measured over 3 months (12 weeks).

The primary endpoint is a composite measured at 3 months (12 weeks). It counts participants with at least one of the following: abemaciclib discontinuation for any reason, an abemaciclib dose reduction, or inability to reach the target full dose of 150 mg BID. The endpoint is described as the number and proportion of participants meeting one or more of those conditions.

A composite can capture several kinds of difficulty within one outcome. In this case, it combines stopping treatment, reducing the dose, and not reaching the target dose. A participant may meet more than one component, but the composite focuses on whether any qualifying component occurred; component counts should not be added together as if they necessarily represented different people.

This endpoint is used to describe dose tolerability and dose attainment over the stated period. It does not directly measure tumor response, recurrence, or survival. Because there is no concurrent control group, the endpoint can characterize outcomes under the study strategy but cannot establish how those outcomes compare with standard dosing in a randomized comparison.

The registry record does not report the observed primary endpoint count, proportion, or an uncertainty estimate. It also does not report component-specific primary endpoint results in the registry record for this analysis.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary outcome is binary at the participant level: a participant either meets at least one of the composite criteria by the stated time or does not. The registry describes the endpoint as a count and proportion. A count gives the number meeting the definition; a proportion relates that count to the analysis population. The denominator matters because it determines which participants are represented in the proportion.

What does a composite endpoint combine?

A composite endpoint groups several defined outcomes under one overall measure. Here, the components are discontinuation for any reason, dose reduction, and inability to reach the target full dose by 3 months (12 weeks). The use of an “or” rule means any one qualifying component is sufficient for a participant to meet the overall endpoint. A person experiencing more than one component still contributes as a participant meeting the composite, rather than as multiple participants.

Composite outcomes can summarize a broader clinical experience, but their meaning depends on the components. The components are not necessarily equally consequential, and a composite result alone cannot show which component occurred most often. Component-specific results are useful for interpretation. The registry lists related secondary outcomes at 12 and 24 weeks, but the record does not give their results.

What can a single-group estimate establish?

In a single-group study, an event proportion describes what was observed among participants receiving the study strategy. It does not estimate a treatment contrast against a concurrent control group. A difference between that observed proportion and an external expectation would not be a randomized comparison, and this record does not specify an external comparator analysis.

Random allocation, when used, can help make groups comparable with respect to measured and unmeasured factors on average. This study is listed as having allocation not applicable and a single-group model. Therefore, differences from results in another study or from a standard-dose population could reflect differences in participants, follow-up, outcome definitions, or other aspects of care, rather than the dosing strategy alone.

How should uncertainty be understood?

A confidence interval is a statistical range that describes uncertainty around an estimate under a specified analysis. For a binary outcome, an interval around a proportion helps convey how precisely the event frequency is estimated. It does not mean that the true value is known to lie within that particular interval with certainty. The registry record does not report a confidence interval for the primary endpoint, so its precision cannot be evaluated.

A p-value, when reported, assesses how compatible data are with a specified statistical model or null hypothesis. It is not a measure of the size or clinical importance of an effect. No primary endpoint p-value is reported in the registry record. In any event, a statistical test in a single group would not create the missing randomized comparison with standard dosing.

What do the planning assumptions mean?

The sample-size assumptions describe planning illustrations based on a stated fraction of an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. These are assumptions for planning illustrations, not observed trial results or evidence of achieved power. Their hypothetical two-arm setup is distinct from the registered single-group study. The record does not report numerical planning results or a trial-specific sample-size justification.

Planning calculations are conditional on choices such as the effect to detect, statistical test, allocation, and significance threshold. If an assumed effect is smaller, a calculation may require more participants to detect it with a specified power; this is a general statistical principle, not a result about this trial. A planning illustration cannot show that a study had a particular probability of detecting an effect after the outcomes are observed. Such a claim would be observed power and is not an appropriate substitute for an estimate and its uncertainty.

Why can over-dispersion matter?

Over-dispersion is a general issue for count outcomes when their variability is greater than the model assumes. A model that does not allow for that extra variation can understate uncertainty. The primary endpoint is described as participants with a composite event, rather than a repeated count of events per participant, and no dispersion parameter is reported. The registry record does not report a model choice or diagnostic assessment for over-dispersion, so no trial-specific conclusion about it can be drawn.

For interpretation, the essential missing pieces are the observed primary count, its analysis denominator, and a measure of uncertainty. The record identifies the endpoint definition and analysis population, but does not report those results or the statistical method used to estimate them.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 17 outcome measures, including the primary composite and secondary outcomes related to dose attainment, discontinuation, dose reductions, diarrhea, adverse events, and a composite at 24 weeks. When several outcomes are examined, the chance of at least one apparently notable result can increase if each is tested separately. Statistical approaches can address this multiplicity, but the registry record does not report whether any adjustment or outcome hierarchy was specified.

The record lists one analysis, but does not describe its method, whether it was prespecified, or how secondary outcomes were handled. Interim analyses and stopping rules are not reported in the registry record. No conclusion about their use should be inferred from the analysis count.

The primary analysis population is described as participants who received at least one dose and did not progress within 12 weeks. One participant with progression in that period was excluded. The record does not report how missing endpoint observations were handled, whether any other participants lacked endpoint data, or whether sensitivity analyses were conducted. It also does not report an analysis population that includes all enrolled participants.

These omissions limit assessment of potential bias and the robustness of the results. Without a stated missing-data approach or primary endpoint results, readers cannot determine whether the analysis denominator reflects all participants eligible under the stated definition or how incomplete follow-up affected the estimate.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: pneumonitis (2.2%), pericardial effusion (1.1%), diarrhea (1.1%), lung infection (1.1%), chronic kidney disease (1.1%).

The registry safety summary lists 90 participants at risk for serious adverse events and 5 participants affected. For other adverse events, it lists 90 at risk and 78 affected. Deaths are listed as 0. These are participant-level summaries as labeled in the record; they should not be treated as counts of all individual events.

The listed serious adverse event terms and percentages are pneumonitis, 2.2%; pericardial effusion, 1.1%; diarrhea, 1.1%; lung infection, 1.1%; chronic kidney disease, 1.1%; and cough, 1.1%. The record does not give term-specific participant counts, timing, or event narratives. These terms and percentages should not be added together to estimate a total number of affected participants.

The safety summaries describe observations in this study, not a comparison with standard-dose abemaciclib or another control. They do not establish causation, and the record does not report the investigator’s attribution of events to treatment. The serious-event summary is also distinct from the primary tolerability composite, whose result is not reported in the registry record.

12. What the Result Does, and Does Not, Mean

The study is designed to describe tolerability and dose attainment under an abemaciclib dose-increasing strategy in early-stage, high-risk HR-positive, HER2-negative breast cancer. The primary endpoint combines discontinuation, dose reduction, and inability to reach the target full dose of 150 mg BID by 3 months (12 weeks). This gives the endpoint a direct relationship to treatment delivery, but the registry record does not report the observed primary result.

The available safety summary gives counts of participants affected by serious and other adverse events, as well as selected serious adverse event terms. Those observations are descriptive. They do not show that the strategy is safer or less safe than standard dosing, because no concurrent comparison group is registered and the record provides no comparative estimate.

The result does not establish whether dose escalation improves tolerability, whether it changes cancer outcomes, or whether its effects differ from standard dosing. It also does not show which component of the primary composite accounts for most of the outcome. Those conclusions would require results and comparisons not reported in the registry record.

More generally, an observed event frequency is not the same as a causal treatment effect. It describes what happened in the study population under the study conditions. A randomized comparison can address a different question by comparing groups assigned to different strategies; this single-group design cannot provide that direct contrast.

The record is still useful for understanding the study question, the endpoint definition, the stated analysis population, and the safety observations recorded. Interpretation should remain limited to those features. The missing primary endpoint result and lack of a control group are substantial constraints on what can be concluded from the information reported.

13. Why This Trial Matters Statistically

Tolerability is not captured only by whether an adverse event is recorded. For a dose-escalation strategy, treatment discontinuation, dose reduction, and reaching the intended dose are also important aspects of how treatment is delivered. The TRADE primary composite makes those dose-management outcomes explicit and sets a defined assessment time of 3 months (12 weeks).

Statistically, this endpoint illustrates both the usefulness and the trade-offs of a composite. Combining outcomes can produce a single summary of several forms of difficulty, but the combined result does not reveal which component drives it. Component-specific estimates are needed to understand whether discontinuation, dose reduction, or failure to reach the target dose is most relevant to the overall finding.

The study also highlights the difference between a motivating comparison and a design capable of estimating it. The rationale discusses a dose-increasing strategy relative to standard dosage, but the registered design is single-group. The study can describe the observed experience under its strategy; it cannot isolate a causal difference from standard dosing without a concurrent comparison.

That distinction matters when communicating tolerability results. A single-group frequency may be useful for planning and for describing a treatment approach, but it should not be presented as proof that one dosing strategy is better tolerated than another. The registry’s stated population, endpoint, and safety summaries are interpretable within those limits.

Finally, reporting the endpoint count, denominator, and uncertainty would be necessary to judge the precision of the primary estimate. Those primary results are not reported in the registry record. The distinction between a clearly defined endpoint and a reported, interpretable result is important for both statistical review and clinical communication.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation is that the primary endpoint result is not reported in the registry record. Without the event count, analysis denominator, and uncertainty estimate, neither the frequency of the composite nor its precision can be evaluated. Although the analysis population is defined, the record does not report its denominator.

The single-group design also limits interpretation. There is no concurrent standard-dose group, and allocation is listed as not applicable. Consequently, observed tolerability and safety summaries cannot establish a comparative effect of the dose-increasing strategy. The study rationale is comparative, but the registered design does not supply that direct contrast.

The primary endpoint combines several outcomes that may differ in meaning: stopping treatment for any reason, reducing the dose, and not reaching the target full dose. Without component-specific results, a composite finding would not identify which event was most common. The available record also does not report details about the dose-escalation schedule beyond the general description of predetermined doses.

The registry does not report the statistical analysis method, multiplicity approach, missing-data handling, interim analyses, or the trial’s sample-size justification. The record’s planning assumptions describe a hypothetical two-arm calculation, not the single-group design. These gaps restrict assessment of precision, robustness, and the relationship between planning and the actual analysis.

The safety information is limited to aggregate counts, selected serious adverse event terms and percentages, and deaths. Event timing, attribution, and comparative context are not reported. These limitations mean the safety figures should be read as descriptive registry observations rather than estimates of comparative risk.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer — NCT06001762.
• Registry record last updated 2026-07-02; status last verified 2026-06.
• Results first posted 2026-07-02.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry identifies TRADE as a phase 2, single-group study sponsored by Dana-Farber Cancer Institute. It lists enrollment of 90, no masking, and allocation as not applicable. The listed status is active, not recruiting. The study start date is 2023-10-05, and the primary completion date is 2025-01-22.

The study evaluates an abemaciclib dose-increasing strategy with endocrine therapy in early-stage, high-risk HR-positive, HER2-negative breast cancer. Its primary endpoint is a 3-month (12-week) composite of abemaciclib discontinuation, dose reduction, or inability to reach the full dose of 150 mg BID. The stated primary analysis population excludes participants who progressed within 12 weeks; the record notes one such participant was excluded.

The registry lists 17 outcome measures and one analysis. It reports aggregate safety figures, but not the primary endpoint result, its denominator, or an uncertainty estimate. Statistical methods, missing-data handling, and multiplicity procedures are not reported in the registry record.